Private Advisor Group LLC Lowers Stock Position in Humana Inc. (NYSE:HUM)

Private Advisor Group LLC lessened its holdings in Humana Inc. (NYSE:HUMGet Rating) by 39.1% during the fourth quarter, Holdings Channel.com reports. The firm owned 24,505 shares of the insurance provider’s stock after selling 15,735 shares during the quarter. Private Advisor Group LLC’s holdings in Humana were worth $11,367,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors and hedge funds have also made changes to their positions in the company. Spire Wealth Management purchased a new stake in Humana in the 4th quarter valued at approximately $30,000. Bell Investment Advisors Inc purchased a new stake in Humana in the 3rd quarter valued at approximately $26,000. BerganKDV Wealth Management LLC boosted its holdings in Humana by 885.7% in the 4th quarter. BerganKDV Wealth Management LLC now owns 69 shares of the insurance provider’s stock valued at $32,000 after purchasing an additional 62 shares in the last quarter. Selective Wealth Management Inc. purchased a new stake in Humana in the 4th quarter valued at approximately $35,000. Finally, PrairieView Partners LLC purchased a new stake in Humana in the 4th quarter valued at approximately $44,000. 94.93% of the stock is currently owned by institutional investors.

A number of research firms have recently issued reports on HUM. UBS Group upgraded shares of Humana from a “neutral” rating to a “buy” rating and lifted their price target for the company from $486.00 to $520.00 in a research report on Wednesday, April 13th. StockNews.com upgraded shares of Humana from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, April 20th. SVB Leerink reduced their price target on shares of Humana from $528.00 to $525.00 and set an “outperform” rating for the company in a research report on Thursday, February 3rd. Wells Fargo & Company lifted their price target on shares of Humana from $491.00 to $512.00 in a research report on Thursday, April 28th. Finally, Zacks Investment Research upgraded shares of Humana from a “sell” rating to a “hold” rating and set a $445.00 price target for the company in a research report on Friday, February 4th. Seven investment analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat, Humana currently has a consensus rating of “Buy” and an average target price of $486.28.

HUM stock opened at $440.59 on Wednesday. The stock has a market capitalization of $55.73 billion, a P/E ratio of 18.69, a PEG ratio of 1.30 and a beta of 0.86. The company has a debt-to-equity ratio of 0.74, a quick ratio of 1.53 and a current ratio of 1.53. Humana Inc. has a one year low of $351.20 and a one year high of $472.68. The company has a 50 day moving average price of $441.98 and a two-hundred day moving average price of $433.58.

Humana (NYSE:HUMGet Rating) last released its earnings results on Wednesday, April 27th. The insurance provider reported $8.04 EPS for the quarter, topping the consensus estimate of $6.79 by $1.25. The firm had revenue of $23.97 billion during the quarter, compared to analysts’ expectations of $23.54 billion. Humana had a net margin of 3.51% and a return on equity of 17.27%. Humana’s revenue for the quarter was up 16.0% on a year-over-year basis. During the same period in the previous year, the company earned $7.67 EPS. Research analysts forecast that Humana Inc. will post 24.65 earnings per share for the current fiscal year.

The company also recently announced a quarterly dividend, which will be paid on Friday, July 29th. Shareholders of record on Thursday, June 30th will be paid a $0.7875 dividend. The ex-dividend date of this dividend is Wednesday, June 29th. This represents a $3.15 annualized dividend and a yield of 0.71%. Humana’s payout ratio is currently 13.36%.

In other news, CAO William Kevin Fleming sold 3,210 shares of the business’s stock in a transaction on Thursday, April 28th. The shares were sold at an average price of $449.68, for a total transaction of $1,443,472.80. Following the completion of the sale, the chief accounting officer now directly owns 884 shares of the company’s stock, valued at approximately $397,517.12. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Samir Deshpande sold 3,957 shares of the company’s stock in a transaction on Tuesday, May 3rd. The stock was sold at an average price of $434.19, for a total transaction of $1,718,089.83. Following the sale, the insider now directly owns 5,529 shares of the company’s stock, valued at $2,400,636.51. The disclosure for this sale can be found here. Insiders have sold a total of 10,644 shares of company stock valued at $4,702,360 over the last three months. Corporate insiders own 0.39% of the company’s stock.

About Humana (Get Rating)

Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. It operates through three segments: Retail, Group and Specialty, and Healthcare Services. The company offers medical and supplemental benefit plans to individuals. It also has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.

See Also

Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc. (NYSE:HUMGet Rating).

Institutional Ownership by Quarter for Humana (NYSE:HUM)

Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.